PRECISE4Q
Financiado
Personalised Medicine by Predictive Modeling in Stroke for better Quality of Lif...
Stroke is one of the most severe medical problems with far-reaching public health and socio-economic impact, gathering momentum in an ageing society. PRECISE4Q sets out to minimise the burden of stroke for the individual and for s...
Stroke is one of the most severe medical problems with far-reaching public health and socio-economic impact, gathering momentum in an ageing society. PRECISE4Q sets out to minimise the burden of stroke for the individual and for society. It will create multi-dimensional data-driven predictive simulation computer models enabling – for the first time – personalised stroke treatment, addressing patient’s needs in four stages: prevention, acute treatment, rehabilitation and reintegration.
Heterogeneous data from multidisciplinary sources will be integrated: genomics, microbiomics, biochemical; imaging including mechanistic biophysiological models of brain perfusion/function; social, lifestyle, gender; economic and worklife, requiring substantial efforts for information extraction, semantic labelling and standardisation.
Novel hybrid model architectures, structured prediction models, complex deep-learning and gradient boosting models will form the Digital Stroke Patient Platform including a Stroke Risk CDSS (Clinical Decision Support System), Treatment Outcomes CDSS, Rehab Programme, Socio-Economic Planning Tool and New QvidLab. The decision support will be tailored to the patient's current life stage thus enabling clinicians to optimise prevention and treatment strategies over time, and will include personalised coping strategies, support of well-being and reintegration into social life and work.
The predictive capability and clinical precision will be validated with real clinical data generated by (i) prospective clinical studies and (ii) retrospective analyses of big data sets: health registries, cohort studies, health insurance data, electronic health records.
PRECISE4Q will have a clinically measurable and sustainable impact leading to better understanding of risk, health and resilience factors. In contrast to current schematic therapy guidelines, it will support patients throughout their life-long journey by personalised strategies for their specific needs.
ver más
Duración del proyecto: 54 meses
Fecha Inicio: 2018-04-18
Fecha Fin: 2022-10-31
Fecha Fin: 2022-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
CHARITE UNIVERSITAETSMEDIZIN BERLIN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
157.44K€ |
Participante
467.21K€ |
Participante